NEWS

June 8, 2023
Travere Therapeutics Announces Presentations of Abstracts at the 60th European Renal Association (ERA) Congress 2023
June 1, 2023
Travere Therapeutics to Present at Upcoming Investor Conferences
May 31, 2023
Travere Therapeutics Announces Positive Topline Results from Cohort 6 in the Phase 1/2 COMPOSE Study of Pegtibatinase in Classical Homocystinuria
May 11, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 4, 2023
Travere Therapeutics Reports First Quarter 2023 Financial Results
May 1, 2023
Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
April 26, 2023
Travere Therapeutics to Report First Quarter 2023 Financial Results
April 13, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2023
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
March 28, 2023
Travere Therapeutics to Present at Upcoming Investor Conferences
March 23, 2023
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
March 14, 2023
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)